Bolt Biotherapeutics (BOLT) — Financial Flexibility Index

Latest as of December 2025: -0.24x

Bolt Biotherapeutics (BOLT) has a Financial Flexibility Index of -0.24x as of December 2025. Free cash flow of $-7.16 Million (operating CF $-7.16 Million minus capex $0.00) represents 0% of total liabilities ($30.24 Million). Check BOLT strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.

Financial Flexibility Index

-0.24x
Free Cash Flow / Total Liabilities

Free Cash Flow

$-7.16 Million
Operating CF − Capex

Total Liabilities

$30.24 Million
USD

Capital Expenditures

$0.00
USD

Bolt Biotherapeutics Financial Flexibility Index (2018–2025)

Historical Financial Flexibility Index trend for Bolt Biotherapeutics across 8 annual periods. See how liquid is Bolt Biotherapeutics's working capital to evaluate short-term liquidity relative to the company's equity base.

Annual Financial Flexibility Index for Bolt Biotherapeutics (2018–2025)

Year-by-year free cash flow to debt coverage for Bolt Biotherapeutics. For the full company profile including market capitalisation, see how much is Bolt Biotherapeutics worth.

Year Flexibility Index Free Cash Flow (USD) Operating CF Total Liabilities YoY Change
2025 -1.32x $-39.78 Million $-39.85 Million $30.24 Million ▲ +8.9%
2024 -1.44x $-61.25 Million $-61.29 Million $42.43 Million ▲ +2.0%
2023 -1.47x $-69.32 Million $-69.53 Million $47.04 Million ▼ -11.3%
2022 -1.32x $-74.55 Million $-76.50 Million $56.30 Million ▼ -39.4%
2021 -0.95x $-54.73 Million $-57.07 Million $57.60 Million ▼ -226.8%
2020 -0.29x $-44.05 Million $-47.31 Million $151.49 Million ▼ -6.1%
2019 -0.27x $-25.84 Million $-26.34 Million $94.29 Million ▲ +8.7%
2018 -0.30x $-9.58 Million $-9.87 Million $31.92 Million
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities